Literature DB >> 8628878

Performance of neuroradiologic examinations by nonradiologists.

A E Flanders1, S J Flanders, D P Friedman, L M Tartaglino, K M Russell.   

Abstract

PURPOSE: To determine the level of participation by nonradiologists in performing neuroradiologic examinations.
MATERIALS AND METHODS: Medicare part B claims data from fiscal year 1992 were analyzed for CPT (current procedural terminology) codes related to computed tomography (CT) and magnetic resonance (MR) imaging of the brain, head and neck, and spine, as well as myelography, angiography, and diskography. Data were tabulated by place of service (hospital-based vs freestanding imaging centers) and by medical specialty.
RESULTS: Among 363,224 Medicare claims for CT and MR imaging of the brain, head and neck, and spine, 91% of the examinations were performed in hospitals and 9% in offices or freestanding centers; 98% of studies were interpreted by a radiologist. The largest share of radiology billing by nonradiologists was from office-based or freestanding imaging centers (9%), versus 2% at hospital-based facilities.
CONCLUSION: Radiologists perform the vast majority of neuroradiologic examinations. Most neuroradiologic examinations performed by nonradiologists are from neurologists at freestanding/office-based imaging centers.

Mesh:

Year:  1996        PMID: 8628878     DOI: 10.1148/radiology.198.3.8628878

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Use trends and geographic variation in neuroimaging: nationwide medicare data for 1993 and 1998.

Authors:  V M Rao; L Parker; D C Levin; J Sunshine; G Bushee
Journal:  AJNR Am J Neuroradiol       Date:  2001-10       Impact factor: 3.825

2.  Now you see me: a pragmatic cohort study comparing first and final radiological diagnoses in the emergency department.

Authors:  Björn Mattsson; David Ertman; Aristomenis Konstantinos Exadaktylos; Luca Martinolli; Wolf E Hautz
Journal:  BMJ Open       Date:  2018-01-13       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.